BioSlice Blog

Subscribe
Visit Blog
By: Arnold & Porter Kaye Scholer LLP

Blog Authors

Adela Williams
Alison Brown
Bonnie Clemence
Bonnie Clemence
Christopher Stothers
Colette Deamer
Daisy Bray
Ewan Townsend
Fenella Fletcher-Flood
Hannah Kerr-Peterson
Ian Dodds-Smith
Jackie Mulryne
John Schmidt
Kathy Harford
Katya Farkas
Keir Heinrich
Laura Whiting
Libby Amos
Lincoln Tsang
Louise Strom
Paul Abbott
Rhiannon Hughes
Richard Dickinson
Silvia Valverde
Tom Fox
Zoe V. Walkinshaw

Latest from BioSlice Blog

On 20 February 2019, the English High Court delivered its eagerly awaited judgment in Canary Wharf v EMA [2019] EWHC 334 (Ch), rejecting the EMA’s argument that the United Kingdom’s withdrawal from the European Union would amount to a frustrating event allowing it to terminate its lease of premises in London. What is frustration Under English law, frustration allows a contract to be set aside on the basis of an unforeseen event which renders…
On 14 February 2019, the Court of Justice of the EU (CJEU) delivered its judgment in Case C-423/17 Netherlands v Warner-Lambert Company, finding in line with the opinion of Advocate General Kokott issued on 4 October 2018, that “carving-out” indications or dosage forms covered by the patent right of a third party, leading to a skinny label for the product, is a request to limit the marketing authorisation for the generic medicinal product. In…
The Falsified Medicines Directive 2011/62/EU (FMD) introduced a new requirement for safety features to appear on the packaging of all prescription-only medicinal products: a unique product identifier and an anti-tampering device (ATD). Commission Delegated Regulation (EU) 2016/161 sets out technical detail around the characteristics of the safety features, how authenticity should be verified and by whom. With the deadline to demonstrate compliance with the Delegated Regulation fast approaching (9 February 2019), we draw your attention…
As we approach one year to go before the application of Regulations (EU) 745/2017 (Medical Devices) and 746/2017 (In Vitro Diagnostic Medical Devices) (applicable in May 2020 and May 2022, respectively), the European Commission has updated its website to collate all of its guidance on the legislation. This includes a recently published series of nine non-binding practical reference guides, which is now available in a new section of the website entitled “Spread the word…
On 18 January, a new statutory instrument, the Human Medicines (Amendment) Regulations 2019 (the Amending Regulations), which amend the Human Medicines Regulations 2012,  was laid before Parliament.  These regulations will come into force on 9 February 2019. The principal purpose of the amendments is to transpose into UK legislation the remaining provisions of Directive 2011/62/EU (the Falsified Medicines Directive), which require two new safety features to appear on the packaging of certain medicinal products,…
Earlier this week, the Commission published a new Regulation amending Regulation 726/2004 that governs the centralised procedure and that sets out the rules for the EMA: Regulation 2019/5. Many of the changes move and consolidate the provisions set out in other Regulations into Regulation 726/2004 on the centralised procedure (known as the Regulation on the Centralised Procedure). We are preparing a more detailed advisory of the implications of the new Regulation, but some headline…
As a New Year present to us all, on 3 January 2019, the MHRA published updated guidance on the regulation of medicines, medical devices and clinical trials in the event that the UK leaves the EU on 29 March 2019 without a deal, known as a “hard Brexit”. Following publication of the technical notice in August 2018, which we considered in an earlier blog, a consultation was launched in order to seek views on…
This week, the EU General Court partially overturned the EU Commission’s decisions in Perindopril (Servier v Commission and Krka v Commission). The judgment was handed down pretty much on the tenth anniversary of the original dawn raids in November 2008. The raids came as a follow-up from the European Commission’s pharma sector enquiry and led to a number of infringement decisions that have also found their way up to the General Court and…
Arnold & Porter’s Future Pharma Forum invites you to a complimentary regulatory seminar aimed at junior lawyers and new joiners in the UK/EU life sciences industry. We will provide a comprehensive introduction to key EU regulatory law topics from an in-house practitioner’s perspective and touch on the implications of Brexit. Topics Overview of the EU pharmaceutical law framework Clinical trials, unlicensed supply and compassionate use Obtaining marketing authorisations Incentives: regulatory data protection, marketing protection, orphan…
On 28 November 2018, the UK Government published draft secondary legislation changing UK intellectual property law relating to exhaustion of IP rights to deal with Brexit. The aim is to ensure that the doctrine of EEA-wide exhaustion continues to apply in the UK post-Brexit, irrespective of whether there is a deal or a no-deal Brexit. What is exhaustion? As summarised in the explanatory memorandum, the exhaustion rule prevents the holder of an intellectual property right from…